Outlook Therapeutics, Inc. (NASDAQ:OTLK) shares fell 6.8% on Friday . The company traded as low as $2.28 and last traded at $2.45, 2,240,537 shares were traded during mid-day trading. A decline of 13% from the average session volume of 2,564,247 shares. The stock had previously closed at $2.63.
A number of research firms recently weighed in on OTLK. ValuEngine upgraded XPO Logistics from a “strong sell” rating to a “sell” rating in a report on Thursday, April 4th. Oppenheimer began coverage on Outlook Therapeutics in a report on Thursday, May 16th. They issued an “outperform” rating and a $12.00 price target on the stock. Ascendiant Capital Markets began coverage on Graham in a report on Monday, April 22nd. They issued a “buy” rating and a $1.59 price target on the stock. CIBC restated a “hold” rating and issued a $3.00 price target on shares of Information Services Group in a report on Thursday, May 16th. Finally, HC Wainwright upped their price target on Ascendant Resources from C$2.00 to C$2.10 in a report on Thursday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $9.00.
The stock’s fifty day simple moving average is $2.15. The company has a market cap of $63.83 million, a PE ratio of -0.23 and a beta of -0.86.
Outlook Therapeutics (NASDAQ:OTLK) last announced its earnings results on Wednesday, May 15th. The company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.08. The company had revenue of $0.64 million for the quarter. As a group, sell-side analysts expect that Outlook Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.
A hedge fund recently bought a new stake in Outlook Therapeutics stock. Chicago Capital LLC bought a new stake in shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 19,450 shares of the company’s stock, valued at approximately $40,000. Chicago Capital LLC owned about 0.07% of Outlook Therapeutics as of its most recent filing with the SEC. 0.79% of the stock is currently owned by institutional investors.
About Outlook Therapeutics (NASDAQ:OTLK)
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.
See Also: Different Types of Derivatives
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.